[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334993-105":59,"doc-detail-334993-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-rheumatoid-arthritis-drug-auranofin-exerts-potent-anti-lymphoma-effect-by-stimulating-txnrd-mediated-ros-generation-and-inhibition-of-energy-metabolism","The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism","","Since survival of lymphoma patients with progression or relapse is poor, new therapeutics are urgently needed. Auranofin (AF), a rheumatoid arthritis drug proposed to inhibit thioredoxin reductases (TXNRDs), shows potent activity against multiple cancers, especially B cell lymphoma. AF interaction with TXNRD converts it into a ROS-generating molecule via disrupted electron transport, while also suppressing energy metabolism through inhibition of mitochondrial complex II and GAPDH, depleting ATP and blocking growth. AF additionally induces PD-L1 expression and immune suppression, and combining AF with anti-PD-1 enhances antitumor activity in an immune-competent mouse model.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-rheumatoid-arthritis-drug-auranofin-exerts-potent-anti-lymphoma-effect-by-stimulating-txnrd-mediated-ros-generation-and-inhibition-of-energy-metabolism/334993/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-rheumatoid-arthritis-drug-auranofin-exerts-potent-anti-lymphoma-effect-by-stimulating-txnrd-mediated-ros-generation-and-inhibition-of-energy-metabolism/334993.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are new lymphoma treatments urgently needed?","Question",{"text":112,"@type":113},"Patients experiencing disease progression or relapse have very poor survival, making more effective therapeutic approaches and drugs urgently necessary.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does auranofin drive cancer cell death according to the study’s mechanism?",{"text":117,"@type":113},"AF interacts with TXNRD to convert it into a ROS-generating molecule by disrupting electron transport, causing electron leakage that forms superoxide. It also suppresses energy metabolism by inhibiting mitochondrial complex II and GAPDH, leading to ATP depletion.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune-related unintended effect does auranofin have, and how was it addressed?",{"text":121,"@type":113},"AF-mediated ROS stress induces PD-L1 expression, indicating immune suppression. Combining AF with an anti-PD-1 antibody enhances anticancer activity in a syngeneic immune-competent mouse B-cell lymphoma model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},334993,1790168532,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Redox Biology 75 (2024) 103245  \nContents lists available at ScienceDirect  \nRedox Biology  \njournal [homepage:](homepage: www.elsevier.com/locate/redox)[ www.elsevier.com/locate/redox](homepage: www.elsevier.com/locate/redox)  \n| The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism\u003Cbr>Mengqi Yanga, d, 1 , Jiaxin Liu a, b, 1 , Jianan Lia, b, 1 , Shijun Wena , Yumin Hua , Wenhua Lua , Jinyun Liu a, c, ** , Peng Huang a, c, *** , Panpan Liu a, b, *\u003Cbr>a Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China b Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China\u003Cbr>c Metabolic Innovation Center, Zhongshan School of Medicine, Platform of Metabolomics Center for Precision Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China\u003Cbr>d Department of Radiation Oncology, Peking University Shenzhen Hospital, Shenzhen, 518036, China |  |  |\n| --- | --- | --- |\n| A R T I C L E I N F O |  | A B S T R A C T |\n| Keywords: Lymphoma Auranofin TXNRD ROS\u003Cbr>ATP\u003Cbr>Immune checkpoint |  | Since the survival of lymphoma patients who experience disease progression or relapse remains very poor, new therapeutic approaches and effective drugs are urgently needed. Here we show that auranofin (AF), an antirheumatoid drug thought to inhibit thioredoxin reductases (TXNRDs) as its mechanism of action, exhibited potent activity against multiple cancer types, especially effective against B cell lymphoma. Surprisingly, aknockdown of TXNRD1 and TXNRD2 did not cause significant cytotoxicity, suggesting that abrogation ofTXNRD enzyme per se was insufficient to cause cancer cell death. Further mechanistic study showed that the interaction of AF with TXNRD could convert this antioxidant enzyme to a ROS-generating molecule via disrupting its electron transport, leading to a leak of electrons that interact with molecular oxygen to form superoxide. AF also suppressed energy metabolism by inhibiting both mitochondria complex II and the glycolytic enzyme GAPDH, leading to a significant depletion of ATP and inhibition of cancer growth in vitro and in vivo. Importantly, we found that the AF-mediated ROS stress could induce PD-L1 expression, revealing an unwanted effect of AF in causing immune suppression. We further showed that a combination of AF with anti-PD-1 antibody could enhance the anticancer activity in a syngeneic immune-competent mouse B-cell lymphoma model. Our study suggests that AF could be a potential drug for lymphoma treatment, and its combination with immune checkpoint inhibitors would be a logical strategy to increase the therapeutic activity. |\n\n1. Introduction  \nLymphoma is one of the most common hematologic malignancies, and its annual incidence rate has increased over recent years [1–3]. Current treatment options for lymphoma include chemotherapy, molecular targeted therapy, immunotherapy, and hematopoietic stem cell transplantation. Despite the major advances in the treatment of lymphoma over the last several decades, the prognosis for patients with relapsed and treatment-resistant disease, and particular sub-types of lymphoma such as mantle cell lymphoma (MCL), remains quite poor [4].  \nThus, development of novel therapeutic agents and more effective treatment regimens to improve the prognosis of lymphoma are important research tasks.  \nAuranofin (AF) is a gold-containing drug originally developed for treatment of rheumatoid arthritis [5,6]. Repurposing of AF for the treatment of cancers has been explored by multiple research groups based on its significant anticancer activity observed in experimental models of various cancer types, including breast cancer [7–9], ovarian cancer [10,11], lung cancer [12–14], multiple myeloma [15–17], leukemia [18–20] and lymphoma [21–24]. Inhibition of thioredoxin  \n","cbCaitq0mIXxe7QP","https://ap.wps.com/l/cbCaitq0mIXxe7QP","pdf",11705936,14,"English","# Introduction\n## Auranofin as a repurposed anticancer drug\n## TXNRD inhibition and proposed mechanisms\n## Clinical evaluation of auranofin in cancer","[{\"question\":\"Why are new lymphoma treatments urgently needed?\",\"answer\":\"Patients experiencing disease progression or relapse have very poor survival, making more effective therapeutic approaches and drugs urgently necessary.\"},{\"question\":\"How does auranofin drive cancer cell death according to the study’s mechanism?\",\"answer\":\"AF interacts with TXNRD to convert it into a ROS-generating molecule by disrupting electron transport, causing electron leakage that forms superoxide. It also suppresses energy metabolism by inhibiting mitochondrial complex II and GAPDH, leading to ATP depletion.\"},{\"question\":\"What immune-related unintended effect does auranofin have, and how was it addressed?\",\"answer\":\"AF-mediated ROS stress induces PD-L1 expression, indicating immune suppression. Combining AF with an anti-PD-1 antibody enhances anticancer activity in a syngeneic immune-competent mouse B-cell lymphoma model.\"}]","The rheumatoid arthritis drug auranofin exerts potent anti-lymphoma effect by stimulating TXNRD-mediated ROS generation and inhibition of energy metabolism | PDF",1790009164,35]